To hear about similar clinical trials, please enter your email below
Trial Title:
Feasibility and Effectiveness of Lymphedema Education Program After Gynecological Cancer Surgery
NCT ID:
NCT06251856
Condition:
Lower Extremity Lymphedema
Conditions: Official terms:
Lymphedema
Conditions: Keywords:
lower limb lymphedema
gynecologic cancer surgery
quality of life
self-efficacy
symptom management model
patient education
Study type:
Interventional
Study phase:
N/A
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Supportive Care
Masking:
Single (Participant)
Intervention:
Intervention type:
Behavioral
Intervention name:
lymphedema education program
Description:
On post-op day 2, patients will receive Symptom Management Model-Based Lower Extremity
Lymphedema Training. Brochures will be introduced and delivered to the patient.
Arm group label:
lymphedema education
Summary:
This study aims to examine the effect of lower extremity lymphedema prevention training
based on the Symptom Management Model on women undergoing gynecological cancer surgery on
lymphedema development, quality of life, and women's self-efficacy. The hypotheses of the
study are:
H1a: The quality of life of women who underwent gynecological cancer surgery and received
lower extremity lymphedema prevention training based on the Symptom Management Model is
statistically significantly higher than the quality of life of women in the control
group.
H1b: The self-efficacy levels of women who underwent gynecological cancer surgery and
received lower extremity lymphedema prevention training based on the Symptom Management
Model are statistically significantly higher than the self-efficacy levels of women in
the control group.
H1c: The frequency of experiencing lower extremity lymphedema symptoms of women who
underwent gynecological cancer surgery and received lower extremity lymphedema prevention
training based on the Symptom Management Model is significantly lower than the frequency
of experiencing lower extremity lymphedema symptoms of women in the control group.
Participants will be given training on lower extremity lymphedema. At the end of the
study, researchers will evaluate the impact of the training on quality of life,
self-efficacy, and lymphedema development.
Detailed description:
The incidence of lower extremity lymphedema following gynecological cancer treatment
varies depending on the type of gynecological cancer. The prevalence of lymphedema varies
between 1-38% in endometrial cancers, 17-81% in cervical cancers, 6-75% in vulvar-vaginal
cancers, and 5-21% in ovarian cancers. Studies have shown that the risk of developing
lymphedema after gynecological cancer persists in the long term, although the majority of
cases occur in the first year. The main factors that increase the risk of developing
lower extremity lymphedema are stated as Body Mass Index (BMI), age, The International
Federation of Gynecology and Obstetrics (FIGO) cancer stage, lymph node dissection and
number of lymph nodes. Lower extremity lymphedema is characterized by symptoms such as
unilateral or bilateral swelling, heaviness, pain, itching, numbness, skin changes,
infection, etc. These symptoms can seriously affect the patient's quality of life by
limiting their daily living activities. Therefore, there is a need for effective
interventions to prevent and manage lower extremity lymphedema associated with cancer
treatment to improve quality of life and well-being. The training is planned to be
structured according to the Symptom Management Model. After gynecological cancer surgery,
women's ability to self-diagnose the symptoms they experience related to lymphedema and
their responses to these symptoms become part of the management process. In this regard,
it is thought that nurse-led education programs positioned in a theoretical framework to
prevent lower extremity lymphedema will enable patients to diagnose the early symptoms of
lymphedema by improving their knowledge, quality of life, self-efficacy, and reduce the
risk of lymphedema. It is anticipated that the model-based nurse-led education program to
be developed in this study will be applicable in the clinic and the evidence obtained
will guide future research. After obtaining institutional permission, data will be
collected by the researcher through a face-to-face interview with women over the age of
18 who meet the inclusion criteria. During this visit, face-to-face information about the
research will be given, written consent will be obtained, and data collection tools will
be introduced and filled in. The risks of the participants will be determined with the
lymphedema risk assessment questionnaire and stratified randomization will be provided
accordingly. Research data will be collected with the Socio-demographic Information Form,
the Information Form on Cancer Diagnosis, the Lymphedema Risk Assessment Questionnaire,
the European Organization for Research and Treatment of Cancer Quality of Life Scale, the
6-Item Self-Efficacy Scale for Chronic Disease Management, Gynecological Cancer
Lymphedema Questionnaire and Lower extremity circumference measurement. After data
collection, the data will be transferred to the Statistical Package for the Social
Sciences (SPSS) 26.0 software package for analysis. The data analysis will include
percentages, mean values, standard deviations and chi-square test, independent sample
t-test, repeated measures ANOVA test, and the corrected Bonferroni test for advanced
analyses.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Women over 18 years of age,
- Able to speak and understand Turkish,
- Not having any cognitive, visual or auditory disabilities,
- Diagnosed with gynecological cancer (cervix, ovary, uterus, endometrium, vulva,
etc.)
- Women who underwent gynecological surgery with inguinal and/or para-aortic and/or
pelvic lymph node dissection due to malignancy.
- Women who have accepted and signed the consent and consent document
Exclusion Criteria:
- Women who diagnosed with venous insufficiency and peripheral artery disease,
- Women with previously diagnosed lower extremity lymphedema
Gender:
Female
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
March 1, 2024
Completion date:
December 1, 2024
Lead sponsor:
Agency:
Koç University
Agency class:
Other
Source:
Koç University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06251856